Loading…
← CockpitCompetitor Analysis › 491000.KS Livsmed Inc.Open in the cockpit ↗

Livsmed Inc.491000.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties
Momentum weak 37
Mkt cap
$687M
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$11.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-28.8 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Next earnings
131 days
29 Mar 2027
Close · KRW₩35,650
1D+10.4%
1W-2.2%
1M-15.0%
3M-22.3%
6M-46.8%
YTD-31.0%
1Yn/a
ATR %12.0%
52w lowhigh62.8% off high

What Livsmed does

Employees: 334

Livsmed at a glance

Size Livsmed (491000.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $687M, the 296th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩35,650 on 18 Nov 2026.

Performance Over six months the shares fell 46.8%, against -12.4% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 88.8% over the last twelve months (peer median +14.8%); the operating margin is -76.6% (peer median 15.6%).

Valuation It trades at 18.1× enterprise value to sales against a peer median of 3.0× (most expensive of 21).

Capital Return on invested capital runs 28.8 points below its cost of capital (5.5% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 89491000.KS 57
Six months, rebased to 100: Livsmed against the median of its 20 peers (local-currency closes).

Livsmed financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩48.3B₩51.2B₩27.1B₩17.3B₩9.68B
Revenue growth—+89%+57%+78%—
Gross profit₩21.9B₩28.8B₩13.9B₩8.97B₩5.08B
EBITDA-₩32.5B-₩19.9B-₩24.9B-₩22.9B-₩16.4B
Net income-₩38.1B-₩22.9B-₩25.6B-₩57.0B-₩59.0B
Free cash flow-₩87.6B-₩42.0B-₩32.0B-₩27.0B-₩18.5B
Capital expenditure₩44.2B₩7.72B₩5.61B₩2.49B₩965M
Total debt₩42.2B₩11.6B₩8.48B₩33.4B₩30.9B

Quarterly statements and history in the cockpit →

Livsmed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%DCTH68838968808500287630123415017575688410300622300326SNTQDEL3011221789688179301367600855INMD603108300453491000.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Livsmed is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%5×10×15×DCTH68838968808500287630123415017575688410300326QDEL3011221789688179301367600855INMD603108491000.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Livsmed is the large dot.

Livsmed competitors and peer comparison

How Livsmed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Livsmed against its 20 peers (data as of 18 Nov 2026)
Measure491000.KSPeer medianRank in peer set
1-month return-15.0%-7.3%6th lowest of 21
6-month return-46.8%-12.4%lowest of 21
Distance from 52-week high-62.8%-35.1%3rd lowest of 21
Revenue growth (TTM)+88.8%+14.8%highest of 21
Operating margin-76.6%15.6%lowest of 21
EV / Sales18.1×3.0×most expensive of 21
ROIC minus cost of capital-28.8 pp+4.1 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%18.1×n/an/a
Delcath Systems DCTHUnited States$685M+75%+38%5%5.3×33.4%+120.2%
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%3.0×11.6%+13.3%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%7.1×29.0%+6.8%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%1.6×10.1%+14.2%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%10.3×31.8%-0.6%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%3.6×-3.3%+23.5%
Japan Lifeline 7575.TJapan$703M+34%+6%19%1.7×-9.5%+2.9%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%3.6×16.2%+25.9%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%3.1×-3.4%+15.7%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%3.8×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%2.9×0.2%+47.5%
QuidelOrtho QDELUnited States$657M-20%-5%-2%1.4×n/an/a
Caina Technology 301122.SZChina$721M+36%+61%0%7.7×n/an/a
AK Medical 1789.HKHong Kong$642M-23%+16%26%2.1×-11.5%+6.7%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%5.8×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%1.8×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%4.5×n/an/a
InMode INMDUnited States$741M-8%+2%18%0.6×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%1.7×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%2.8×-1.9%+11.8%

Questions

Which companies are Livsmed's closest peers?
The cockpit's peer set: Delcath Systems (DCTH), Shenzhen Lifotronic Technology (688389.SS), Shanghai Sanyou Medical (688085.SS), Shenzhen Sunnypol Optoelectornics (002876.SZ), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Shanghai INT Medical Instruments (1501.HK), Japan Lifeline (7575.T), SWS Hemodialysis Care (688410.SS).
Is Livsmed expensive compared with its peers?
On ev / sales it trades at 18.1× against a peer median of 3.0×, most expensive of 21 in its peer set.
How has Livsmed stock performed?
Over six months to 18 Nov 2026 the shares returned -46.8% against -12.4% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.